Developer docs
API playgroundTry for free, no card

Search company profiles

Neok Bio

Full company profile

uuid003qewd

Namestring
Neok Bio
Legal namestring
NEOK Bio, Inc.
Websiteurl
neokbio.com
Company typeenum
Private
Founded yearint
2025
Descriptiontext

NEOK Bio is a clinical-stage oncology therapeutics company developing bispecific antibody drug conjugates (ADCs) for the treatment of solid tumor cancers. Founded in 2025 and headquartered in Palo Alto, California as a U.S. subsidiary of Korean biotech ABL Bio, the company is focused on dual-targeting ADC strategies designed to improve safety and efficacy relative to conventional monovalent ADCs. Its lead pipeline consists of two candidates: NEOK001, a B7-H3/ROR1 bispecific ADC, and NEOK002, an EGFR/MUC1 bispecific ADC, both targeting thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition. Initial clinical data is expected in 2027.

The company's technology stack is anchored by a proprietary Topo-1-based ADC platform that combines intelligent target-antigen selection with the SYNtecan E™ linker-payload technology and the exatecan payload. Exatecan is positioned as offering increased permeability, greater bystander effect, and lower resistance risk than other approved Topo-1 inhibitors (notably, it is not an MDR1 substrate). For NEOK002, the company has licensed Biocytogen's RenLite® bispecific antibody platform to access fully human bispecific antibody discovery capabilities. NEOK Bio has secured FDA IND clearance for both lead candidates and initiated Phase 1 clinical trials in May 2026.

The business model is pre-revenue and clinical-stage, with revenue mechanics expected to flow from future drug development and commercialization, including potential licensing transactions. To date, the company has raised approximately $100 million across two tranches led by ABL Bio ($75M Series A in November 2025 and $25M in March 2026). The company has no commercialized products, no distribution channels, and no announced customers or partnerships beyond its technology licensing relationship with Biocytogen and its strategic backing from ABL Bio. ABL Bio has publicly indicated that NEOK Bio is structured as a vehicle for potential M&A and a future Nasdaq listing.

Short descriptiontext

NEOK Bio is a clinical-stage biotech developing bispecific antibody drug conjugates for solid tumor cancers. Founded in 2025 and backed by ABL Bio, the company is advancing two lead candidates, NEOK001 (B7-H3/ROR1) and NEOK002 (EGFR/MUC1), both in Phase 1 trials.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersPalo Alto, United States
HQ citystring
Palo Alto
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody drug conjugates, oncology therapeutics, cancer drug development, antibody engineering platforms, topoisomerase inhibitor ADCs
Industry2 codes
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

As a clinical-stage oncology therapeutics company, NEOK Bio is focused on developing bispecific ADC drug candidates through clinical trials with the goal of achieving regulatory approval and commercializing novel cancer treatments. The company is pre-revenue as of the current period, with initial clinical data expected in 2027.

neokbio.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

NEOK Bio is a clinical-stage oncology therapeutics company developing bispecific antibody drug conjugates (ADCs) for solid tumor cancers. It is advancing two lead drug candidates — NEOK001 (B7-H3/ROR1) and NEOK002 (EGFR/MUC1) — through Phase 1 clinical trials using a proprietary Topo-1-based ADC platform with SYNtecan E™ linker-payload technology and an exatecan payload. Both candidates target advanced solid tumors initially focused on thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • NEOK001 demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies
+2 more records
Product overview1 text field

Neok Bio is a clinical-stage oncology therapeutics company developing a pipeline of differentiated bispecific antibody drug conjugates (ADCs) leveraging a novel Topo-1-based platform technology with proprietary SYNtecan E™ linker-payload technology. The company is advancing two lead bispecific ADC drug candidates: NEOK001 (targeting ROR1 and B7-H3) and NEOK002 (targeting EGFR and MUC1), both designed to improve outcomes for cancer patients by targeting proteins broadly expressed across tumor types with significant unmet needs, initially focusing on thoracic, gastrointestinal, and gynecological cancers.

Product and service2 records
1NEOK001
CategoryDrug Candidate
Description

Bispecific antibody drug conjugate (ADC) targeting B7-H3 and ROR1, in Phase 1 clinical development for advanced solid tumors (initially thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition). Demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies; positioned to address limitations of single-target ADCs in selectivity, efficacy, and resistance.

2NEOK002
CategoryDrug Candidate
Description

Bispecific antibody drug conjugate (ADC) targeting EGFR and MUC1, in Phase 1 clinical development for advanced solid tumors (initially thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition). Built using Biocytogen's RenLite® bispecific antibody platform licensed to NEOK Bio; demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-01-01
Description

Biocytogen developed and licensed its bispecific antibody technology (RenLite® platform) to NEOK Bio in 2024 for the development of NEOK002, an EGFR/MUC1-targeting bispecific ADC. The FDA IND clearance for NEOK002 in 2026 validated Biocytogen's RenLite platform. This partnership provides NEOK Bio with access to fully human bispecific antibody discovery capabilities.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharma co-developer of Enhertu with Daiichi Sankyo. Relevant as a broad incumbent with significant Topo-1 ADC franchise investment that competes with NEOK Bio's payload and target strategy.

TypeDirect peer
Description

Clinical-stage ADC developer focused on next-generation antibody drug conjugates for solid tumors. Closely comparable to NEOK Bio as a venture/strategic-backed ADC biotech pursuing differentiated payload and conjugation strategies in oncology.

TypeDirect peer
Description

Clinical-stage ADC company developing differentiated antibody drug conjugates for cancer. Highly comparable as a peer ADC-focused biotech developing novel linker-payload and targeting strategies for solid tumors.

TypeEmerging player
Description

Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Comparable to NEOK Bio in stage and modality focus, though with a broader mix of ADC and immune-engager programs.

TypeEmerging player
Description

Clinical-stage oncology company developing immune-stimulating antibody-drug conjugates. Comparable as a peer clinical-stage ADC biotech, though with a distinct immune-stimulatory payload strategy.

TypeBroad incumbent
Description

Global pharma company and pioneer of Topo-1-based ADCs (Enhertu, Dato-DXd). Comparable as the category-defining incumbent in Topo-1 ADC payloads — directly relevant to NEOK Bio's exatecan-based strategy.

TypeBroad incumbent
Description

Korean biotech parent of NEOK Bio and world-leader in bispecific antibody engineering. Directly comparable as both parent and peer — develops bispecific antibodies including ADCs and serves as NEOK Bio's primary technology and capital partner.

TypeEmerging player
Description

Chinese antibody discovery platform company that licensed its RenLite® bispecific antibody technology to NEOK Bio. Directly comparable as a peer in bispecific antibody platforms and ADC enabling technologies.

9Duality Biologics
TypeDirect peer
Description

Developer of bispecific ADCs using proprietary linker-payload platforms for oncology. Directly comparable to NEOK Bio's bispecific ADC approach and SYNtecan E™-style platform architecture, with overlapping target and payload strategies.

TypeBroad incumbent
Description

Pfizer acquired Seagen for its ADC platform and commercialized ADCs (Adcetris, Padcev). Broad incumbent in the ADC space with significant R&D investment in next-generation conjugates overlapping NEOK Bio's territory.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neok Bio

Oncology Therapeuticsneokbio.com

NEOK Bio is a clinical-stage biotech developing bispecific antibody drug conjugates for solid tumor cancers. Founded in 2025 and backed by ABL Bio, the company is advancing two lead candidates, NEOK001 (B7-H3/ROR1) and NEOK002 (EGFR/MUC1), both in Phase 1 trials.

What Neok Bio does

NEOK Bio is a clinical-stage oncology therapeutics company developing bispecific antibody drug conjugates (ADCs) for the treatment of solid tumor cancers. Founded in 2025 and headquartered in Palo Alto, California as a U.S. subsidiary of Korean biotech ABL Bio, the company is focused on dual-targeting ADC strategies designed to improve safety and efficacy relative to conventional monovalent ADCs. Its lead pipeline consists of two candidates: NEOK001, a B7-H3/ROR1 bispecific ADC, and NEOK002, an EGFR/MUC1 bispecific ADC, both targeting thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition. Initial clinical data is expected in 2027.

The company's technology stack is anchored by a proprietary Topo-1-based ADC platform that combines intelligent target-antigen selection with the SYNtecan E™ linker-payload technology and the exatecan payload. Exatecan is positioned as offering increased permeability, greater bystander effect, and lower resistance risk than other approved Topo-1 inhibitors (notably, it is not an MDR1 substrate). For NEOK002, the company has licensed Biocytogen's RenLite® bispecific antibody platform to access fully human bispecific antibody discovery capabilities. NEOK Bio has secured FDA IND clearance for both lead candidates and initiated Phase 1 clinical trials in May 2026.

The business model is pre-revenue and clinical-stage, with revenue mechanics expected to flow from future drug development and commercialization, including potential licensing transactions. To date, the company has raised approximately $100 million across two tranches led by ABL Bio ($75M Series A in November 2025 and $25M in March 2026). The company has no commercialized products, no distribution channels, and no announced customers or partnerships beyond its technology licensing relationship with Biocytogen and its strategic backing from ABL Bio. ABL Bio has publicly indicated that NEOK Bio is structured as a vehicle for potential M&A and a future Nasdaq listing.

Neok Bio firmographics

Firmographics
Name
Neok Bio
Legal name
NEOK Bio, Inc.
Website
https://neokbio.com
Company type
Private
Founded year
2025
Operating status
Operating
Headcount range
1–10 employees
Short description
NEOK Bio is a clinical-stage biotech developing bispecific antibody drug conjugates for solid tumor cancers. Founded in 2025 and backed by ABL Bio, the company is advancing two lead candidates, NEOK001 (B7-H3/ROR1) and NEOK002 (EGFR/MUC1), both in Phase 1 trials.
Ownership category
akta.pro rank

Neok Bio industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Bispecific antibody drug conjugates
  • Oncology therapeutics
  • Cancer drug development
  • Antibody engineering platforms
  • Topoisomerase inhibitor ADCs

Where Neok Bio is headquartered

Location

Headquarters

HQ city
Palo Alto
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Neok Bio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Drug Development and Commercialization: As a clinical-stage oncology therapeutics company, NEOK Bio is focused on developing bispecific ADC drug candidates through clinical trials with the goal of achieving regulatory approval and commercializing novel cancer treatments. The company is pre-revenue as of the current period, with initial clinical data expected in 2027.

Go-to-market motion1 record

Marketing channels3 records

Neok Bio product offering

Product offering

Core offering

NEOK Bio is a clinical-stage oncology therapeutics company developing bispecific antibody drug conjugates (ADCs) for solid tumor cancers. It is advancing two lead drug candidates — NEOK001 (B7-H3/ROR1) and NEOK002 (EGFR/MUC1) — through Phase 1 clinical trials using a proprietary Topo-1-based ADC platform with SYNtecan E™ linker-payload technology and an exatecan payload. Both candidates target advanced solid tumors initially focused on thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition.

Product overview

Neok Bio is a clinical-stage oncology therapeutics company developing a pipeline of differentiated bispecific antibody drug conjugates (ADCs) leveraging a novel Topo-1-based platform technology with proprietary SYNtecan E™ linker-payload technology. The company is advancing two lead bispecific ADC drug candidates: NEOK001 (targeting ROR1 and B7-H3) and NEOK002 (targeting EGFR and MUC1), both designed to improve outcomes for cancer patients by targeting proteins broadly expressed across tumor types with significant unmet needs, initially focusing on thoracic, gastrointestinal, and gynecological cancers.

Differentiator

Problem solved

Functional benefit

Products and services

  • NEOK001 Bispecific antibody drug conjugate (ADC) targeting B7-H3 and ROR1, in Phase 1 clinical development for advanced solid tumors (initially thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition). Demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies; positioned to address limitations of single-target ADCs in selectivity, efficacy, and resistance.
  • NEOK002 Bispecific antibody drug conjugate (ADC) targeting EGFR and MUC1, in Phase 1 clinical development for advanced solid tumors (initially thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition). Built using Biocytogen's RenLite® bispecific antibody platform licensed to NEOK Bio; demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies.

Quantifiable outcome

  • NEOK001 demonstrated superior in vivo efficacy compared to monovalent ADCs in preclinical studies
  • +2 more outcomes

Companies that use Neok Bio

Customer profile

Segments1 record

Ideal customer profiles2 records

Neok Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Neok Bio partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BiocytogencoreTechnology or Integration · 1 January 2024Biocytogen developed and licensed its bispecific antibody technology (RenLite® platform) to NEOK Bio in 2024 for the development of NEOK002, an EGFR/MUC1-targeting bispecific ADC. The FDA IND clearance for NEOK002 in 2026 validated Biocytogen's RenLite platform. This partnership provides NEOK Bio with access to fully human bispecific antibody discovery capabilities.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Neok Bio competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: Global pharma co-developer of Enhertu with Daiichi Sankyo. Relevant as a broad incumbent with significant Topo-1 ADC franchise investment that competes with NEOK Bio's payload and target strategy.
  • Daiichi Sankyo: Global pharma company and pioneer of Topo-1-based ADCs (Enhertu, Dato-DXd). Comparable as the category-defining incumbent in Topo-1 ADC payloads — directly relevant to NEOK Bio's exatecan-based strategy.
  • ABL Bio: Korean biotech parent of NEOK Bio and world-leader in bispecific antibody engineering. Directly comparable as both parent and peer — develops bispecific antibodies including ADCs and serves as NEOK Bio's primary technology and capital partner.
  • Pfizer (Seagen): Pfizer acquired Seagen for its ADC platform and commercialized ADCs (Adcetris, Padcev). Broad incumbent in the ADC space with significant R&D investment in next-generation conjugates overlapping NEOK Bio's territory.

Direct peers

  • ProfoundBio: Clinical-stage ADC developer focused on next-generation antibody drug conjugates for solid tumors. Closely comparable to NEOK Bio as a venture/strategic-backed ADC biotech pursuing differentiated payload and conjugation strategies in oncology.
  • Mersana Therapeutics: Clinical-stage ADC company developing differentiated antibody drug conjugates for cancer. Highly comparable as a peer ADC-focused biotech developing novel linker-payload and targeting strategies for solid tumors.
  • Duality Biologics: Developer of bispecific ADCs using proprietary linker-payload platforms for oncology. Directly comparable to NEOK Bio's bispecific ADC approach and SYNtecan E™-style platform architecture, with overlapping target and payload strategies.

Emerging players

  • Pyxis Oncology: Clinical-stage oncology company developing antibody-drug conjugates and immunotherapies. Comparable to NEOK Bio in stage and modality focus, though with a broader mix of ADC and immune-engager programs.
  • Bolt Biotherapeutics: Clinical-stage oncology company developing immune-stimulating antibody-drug conjugates. Comparable as a peer clinical-stage ADC biotech, though with a distinct immune-stimulatory payload strategy.
  • Biocytogen: Chinese antibody discovery platform company that licensed its RenLite® bispecific antibody technology to NEOK Bio. Directly comparable as a peer in bispecific antibody platforms and ADC enabling technologies.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Neok Bio social profiles

Digital presence

Neok Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neok Bio leadership team

Management profile

Number of profiles

Profiles9 records

Neok Bio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neok Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neok Bio

What does Neok Bio do?

NEOK Bio is a clinical-stage oncology therapeutics company developing bispecific antibody drug conjugates (ADCs) for solid tumor cancers. It is advancing two lead drug candidates — NEOK001 (B7-H3/ROR1) and NEOK002 (EGFR/MUC1) — through Phase 1 clinical trials using a proprietary Topo-1-based ADC platform with SYNtecan E™ linker-payload technology and an exatecan payload. Both candidates target advanced solid tumors initially focused on thoracic, gastrointestinal, and gynecological cancers sensitive to Topo-1 inhibition.

Is Neok Bio a public or private company?

Neok Bio is a private company. It is classified as corporate owned and is currently operating.

When was Neok Bio founded?

Neok Bio was founded in 2025. It employs 1 to 10 people.

Where is Neok Bio based?

Neok Bio is headquartered in Palo Alto, United States, in the North America region.

How does Neok Bio make money?

One revenue line is on record: drug Development and Commercialization.

Who are Neok Bio's main competitors?

Broad incumbents on record are AstraZeneca, Daiichi Sankyo, ABL Bio and Pfizer (Seagen). Direct peers are ProfoundBio, Mersana Therapeutics and Duality Biologics. Emerging players are Pyxis Oncology, Bolt Biotherapeutics and Biocytogen.

Does Neok Bio have an API?

No public API is recorded for Neok Bio.

What industry is Neok Bio in?

Neok Bio's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogNEOK Bio Initiates Phase 1 Clinical Trials of Both Lead Bispecific ADCsNEOK Bio, a clinical-stage oncology therapeutics company, has initiated Phase 1 clinical trials for its two lead bispecific ADC candidates, NEOK001 and NEOK002, for the treatment of advanced solid tumors. The trials will evaluate safety, tolerability, and efficacy in patients whose cancers co-express the targeted proteins (B7-H3/ROR1 for NEOK001 and EGFR/MUC1 for NEOK002). Initial clinical data from both studies is expected in 2027, with the company highlighting the speed of advancing two programs from preclinical to first-in-human dosing.Precedence ResearchAntibody Drug Conjugates Market Size to Hit USD 34.80 Bn by 2035The global antibody drug conjugates (ADC) market is valued at USD 12.69 billion in 2025 and is projected to reach USD 34.80 billion by 2035, growing at a CAGR of 10.61%, driven by rising cancer prevalence and increased R&D investment in targeted oncology therapies. North America dominates with 50% market share, while Asia Pacific is expected to grow at the fastest rate of 19% CAGR over the forecast period. Key recent developments include C4 Therapeutics' April 2026 collaboration with Roche to develop degrader-antibody conjugates, and NEOK Bio's $75 million Series A funding round to build a bispecific ADC pipeline.Business Wire BlogNEOK Bio Presentations at AACR 2026 Annual Meeting Showcase Potential of a Differentiated Bispecific Antibody Drug Conjugate PipelineNEOK Bio will present preclinical data for its bispecific ADCs NEOK001 and NEOK002 at AACR 2026 in San Diego. Both candidates received FDA IND approval in Q1 2026, with Phase 1 trials planned for Q2 2026 and initial data expected in 2027.AijournBiocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid TumorsBiocytogen's partner NEOK Bio received FDA IND clearance for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate (ADC) candidate for solid tumors. The ADC was built on a bispecific antibody originally developed by Biocytogen and licensed to NEOK Bio in 2024. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and report initial data in 2027.AijournBiocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid TumorsBiocytogen's partner NEOK Bio received FDA IND clearance for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate (ADC) candidate for solid tumors. The bispecific antibody was originally developed by Biocytogen using its RenLite platform and licensed to NEOK Bio in 2024. NEOK Bio plans to initiate a Phase 1 clinical study in Q2 2026, with initial data expected in 2027.Financial PostBiocytogen Announces FDA IND Clearance for Partner NEOK Bio's NEOK002 Targeting Solid TumorsBiocytogen's partner NEOK Bio received FDA IND clearance for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate (ADC) for solid tumors. NEOK002 was developed using a bispecific antibody originally created by Biocytogen and licensed to NEOK Bio in 2024; a Phase 1 clinical study is planned for Q2 2026 with initial data expected in 2027. The milestone validates Biocytogen's RenLite® bispecific antibody platform, which features a common light chain design.PharmiWeb.comBiocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid TumorsBiocytogen's partner NEOK Bio received FDA IND clearance for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in Q2 2026 with initial data expected in 2027. The ADC candidate was developed using a bispecific antibody originally created by Biocytogen and licensed to NEOK Bio in 2024.PharmiWeb.comBiocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid TumorsNEOK Bio, Inc. announced that the U.S. FDA has cleared its investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate (ADC) for solid tumors. The bispecific ADC was built on a fully human bispecific antibody originally developed by Biocytogen and licensed to NEOK Bio in 2024, with a Phase 1 clinical study planned for Q2 2026 and initial data expected in 2027. This milestone validates the therapeutic potential of Biocytogen's RenLite® platform and represents a significant step forward in the clinical advancement of a differentiated solid tumor treatment.Business Wire IndiaBiocytogen Announces FDA IND Clearance for Partner NEOK Bio's NEOK002 Targeting Solid TumorsBiocytogen's partner NEOK Bio received FDA IND clearance for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate for solid tumors, marking a key milestone for the licensed bispecific antibody program. NEOK Bio plans to initiate a Phase 1 clinical study in Q2 2026 and report initial data in 2027. The clearance validates Biocytogen's RenLite platform, which provides fully human bispecific antibodies with a common light chain design, licensed to NEOK Bio in 2024.MorningstarBiocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid TumorsBiocytogen's partner NEOK Bio received FDA IND clearance for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate (ADC) candidate for solid tumors, developed using Biocytogen's bispecific antibody technology licensed in 2024. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 with initial data expected in 2027. The milestone validates Biocytogen's RenLite platform for bispecific antibody discovery and represents continued advancement of their partnered therapeutic pipeline.